ライフサイエンスコーパス: modafinil

1 on requiring hospital admission while taking modafinil).

2 apses in brain slices from mice treated with modafinil.

3 ic wake-promoting action of amphetamines and modafinil.

4 o 5.96) for CBT and 1.20 (-2.83 to 5.23) for modafinil.

5 diates the effect of the antinarcolepsy drug modafinil.

6 pendent actions for methylphenidate, but not modafinil.

7 expression or pharmacological activation via modafinil.

8 rotonin and norepinephrine transporters than modafinil.

9 mprovements in response inhibition following modafinil.

10 We also examined modafinil (0.075 to 75 mg/kg) on Pavlovian fear conditio

11 A low dose of pretraining modafinil (0.75 mg/kg) enhanced memory of contextual fea

12 2-[(Diphenylmethyl)sulfinyl]acetamide (modafinil, (+/-)-1) is a unique dopamine uptake inhibito

13 ebo-controlled, three-way crossover study of modafinil (100 mg and 200 mg), was conducted in an indep

14 ast 4 weeks, were randomly assigned to daily modafinil (100 mg on days 1 to 14; 200 mg on days 15 to

15 %; placebo, 11%; p = 0.044) and nervousness (modafinil, 12%; placebo, 3%; p = 0.024) were the most co

16 received either lactose placebo (n = 19) or modafinil 200 mg (n = 20) after 1 night of sleep depriva

17 tested the effects of adjunctive single-dose modafinil 200 mg on rule-related 4-30 Hz oscillations in

18 task to examine effects of a single dose of modafinil (200 mg) on response inhibition and underlying

19 Headache (modafinil, 23%; placebo, 11%; p = 0.044) and nervousness

20 rticipants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every mornin

21 from baseline to day 28 (mean score change: modafinil, 5.29; 95% CI, 2.57 to 8.02; placebo, 5.09; 95

22 aking amantadine (49 [39%] of 127 patients), modafinil (50 [40%] of 125 patients), and methylphenidat

23 th score < 10) was significantly higher with modafinil (51%) than with placebo (27%) (p < 0.01), but

24 A high dose of modafinil (75 mg/kg ip) given before training improved a

25 late this process, as well as the effects of modafinil (a putative cognitive enhancer) on option gene

26 Modafinil, a wake-promoting drug used to treat narcoleps

27 To determine potential pathways via which modafinil acts, we administered a range of doses of moda

28 Within the AD group modafinil administration improved response inhibition (r

29 Modafinil administration was associated with significant

30 Moreover, caffeine and modafinil affected wakefulness-induced changes in functi

31 Modafinil also decreased [(11)C]cocaine binding potentia

32 Patients who were receiving modafinil also had a reduction in the frequency and dura

33 This low dose of modafinil also increased the number of Fos-immunoreactiv

34 modafinil sequence; 35 (25%) patients to the modafinil, amantadine, methylphenidate, and placebo sequ

35 Moreover, modafinil, an anti-narcoleptic drug with ill-defined mec

36 ted effects of novel DAT inhibitors that are modafinil analogs and have a range of binding profiles a

37 A series of modafinil analogues have been reported so far, but more

38 Herein, we report a series of modafinil analogues that have an atypical DAT inhibitor

39 Our continuous effort to find modafinil analogues with higher inhibitory activity on a

40 the wake-promoting antinarcoleptic compounds modafinil and amphetamine increase extracellular dopamin

41 r congenital malformations after exposure to modafinil and armodafinil during pregnancy.

42 ent groups included insomnia (eight [7%] for modafinil and eight [7%] for combination therapy) and an

43 (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synt

44 ole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups.

45 Modafinil and methylphenidate are medications that inhib

46 The CNS stimulants modafinil and methylphenidate are recommended for the tr

47 Both modafinil and methylphenidate pretreatments potentiated

48 ination therapy) and anxiety (three [3%] for modafinil and nine [8%] for combination therapy).

49 ociation between first-trimester exposure to modafinil and risk of major congenital malformations.

50 (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo.

51 atment (114 assigned to CBT, 114 assigned to modafinil, and 108 assigned to combination therapy).

52 43.7) with amantadine, 39.0 (36.6-41.4) with modafinil, and 38.6 (36.2-41.0) with methylphenidate (p=

53 Methylphenidate, modafinil, and amantadine are commonly prescribed medica

54 Rasagiline, modafinil, and doxepin are associated with improvement i

55 ivity to caffeine, reduced-responsiveness to modafinil, and increased homeostatic response to prolong

56 5 (25%) patients to the amantadine, placebo, modafinil, and methylphenidate sequence; 34 (24%) patien

57 Amantadine, modafinil, and methylphenidate were not superior to plac

58 a, 3,4-methylenedioxymethamphetamine (MDMA), modafinil, and methylphenidate.

59 ness of cognitive behavioural therapy (CBT), modafinil, and their combination for treating multiple s

60 Lorazepam, modafinil, and valproate did not influence P50 suppressi

61 rtness-promoting medications armodafinil and modafinil are associated with improved alertness during

62 However, these drugs and others, including modafinil, are being increasingly used by healthy people

63 ypical dopamine reuptake inhibitors, such as modafinil, are used for the treatment of sleeping disord

64 study aims to further examine the effects of modafinil as a cognitive enhancer on hippocampus-depende

65 Future trials with R-modafinil as a substitute therapy with the potential ben

66 a neurobiological rationale for implementing modafinil as an adjunct in the treatment of alcohol depe

67 Treatment with modafinil, as compared with placebo, resulted in a modes

68 These data suggest that adjunctive modafinil at doses of 100-200 mg a day may improve depre

69 These findings demonstrate that modafinil at least partly exerts its effects by targetin

70 ith spontaneous wakefulness, we administered modafinil at midnight, during the normal waking period o

71 ian phase or ambient light, we also injected modafinil at noon on a normal light/dark cycle or in con

72 hetamine, dexamphetamine, lisdexamphetamine, modafinil, atomoxetine, clonidine) during pregnancy and

73 No associations were found for modafinil, atomoxetine, clonidine, and guanfacine.

74 (+/-)-, R-, and S-modafinil bind to the DAT and inhibit DA uptake less pot

75 In this pilot study, modafinil blocked dopamine transporters and increased do

76 olone, a gap junction inhibitor, antagonized modafinil, but not methylphenidate potentiation of cocai

77 These findings indicate that modafinil can improve response inhibition in alcohol-dep

78 that methylphenidate, dextroamphetamine, and modafinil cause knapsack value attained in the task to d

79 Modafinil, CBT, and combination therapy were associated

80 Most common adverse events for modafinil-containing treatment groups included insomnia

81 espite these benefits, patients treated with modafinil continued to have excessive sleepiness and imp

82 Modafinil decreased mean (SD) [(11)C]raclopride binding

83 Compared with placebo, modafinil decreased nighttime sleep latency and increase

84 Modafinil did not adversely affect daytime sleep as comp

85 Pretraining modafinil did not affect cued conditioning at any dose t

86 When given only before testing, modafinil did not affect water maze performance.

87 Modafinil did not improve cognitive control in all schiz

88 In contrast to previous studies, modafinil did not produce statistically significant incr

89 R-modafinil displays an in vitro profile different from co

90 The pharmacologic agent modafinil enhances cognitive control functions in both h

91 up study assessed the efficacy and safety of modafinil for the treatment of residual daytime sleepine

92 We evaluated the use of modafinil for treating sleepiness in patients with this

93 plasticity in these neurons, suggesting that modafinil functions through activation of the dopamine s

94 ssion rates were significantly higher in the modafinil group (44% and 39%) compared with the placebo

95 n IDS score was significantly greater in the modafinil group (mean dose, 177 mg/day) compared with th

96 The modafinil group (n=14), relative to placebo group (n=13)

97 ments for the secondary outcomes; 47% of the modafinil group and 23% of the placebo group stated that

98 gent hypomania or mania (six patients in the modafinil group and five in the placebo group) or hospit

99 ve symptoms was significantly greater in the modafinil group by week 2, and this greater improvement

100 gher cognitive function; participants in the modafinil group worked more efficiently when solving wor

101 Modafinil had no effect on cancer-related fatigue and sh

102 any dose tested, and immediate posttraining modafinil had no effect on either cued or contextual fea

103 Modafinil has been shown to promote wakefulness and some

104 (+/-)-Modafinil has piqued interest as a treatment for attenti

105 lar to that found in the wake-promoting drug modafinil have been synthesized.

106 DA uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity

107 tive at reducing daytime somnolence (such as modafinil) hold potential for the treatment of fatigue i

108 Some piperidine-based nocaine/modafinil hybrid ligands have been designed, synthesized

109 Modafinil improved performance on tests of higher cognit

110 into account when considering treatment with modafinil in AD.

111 aluate the efficacy and safety of adjunctive modafinil in bipolar depression, which is often characte

112 articipants revealed a normalizing effect of modafinil in cocaine-dependent participants.

113 These endpoints were not affected by modafinil in either species.

114 Focal response to modafinil in the left dorsolateral prefrontal cortex and

115 to evaluate the efficacy and tolerability of modafinil in the management of fatigue in patients with

116 ess for potential abuse of and dependence on modafinil in vulnerable populations.

117 We found that 75 mg/kg modafinil increased Fos immunoreactivity in the tuberoma

118 ault mode network, which was associated with modafinil-induced improvement in cognitive control in al

119 ients with initial poor response inhibition, modafinil-induced SSRT improvement was accompanied by gr

120 hip between baseline response inhibition and modafinil-induced SSRT improvement was mediated by these

121 To contrast modafinil-induced wakefulness with spontaneous wakefulne

122 The effect of modafinil interacted with the abstinence week and was as

123 Modafinil is a wake promoting compound with high potenti

124 Modafinil is an increasingly popular wake-promoting drug

125 Modafinil is approved by the U.S. Food and Drug Administ

126 Modafinil is known to facilitate electrotonic neuronal c

127 Modafinil is now considered the first-line treatment for

128 e some evidence of benefits for galantamine, modafinil, levodopa, rotigotine, clozapine, duloxetine,

129 We show that methylphenidate, but not modafinil, maintained intravenous self-administration in

130 Modafinil may be a useful adjunct treatment for the mana

131 These observations suggest that modafinil may promote waking via activation of TMN and o

132 lude CNS stimulants (eg, methylphenidate and modafinil), medications used in patients with memory imp

133 the normally robust wake-promoting action of modafinil, methamphetamine, and the selective DAT blocke

134 The R-enantiomer of modafinil might have unique pharmacological properties t

135 ffects of 4-week fixed-dose daily adjunctive modafinil (MOD) 200 mg, in a randomized double-blind, pl

136 (+/-)-Modafinil (MOD) is used clinically for the treatment of

137 (+/-)Modafinil ((+/-)MOD) and its R-enantiomer (R-modafinil;

138 Patients received modafinil (n = 77) (200 mg/d, Week 1; 400 mg/d, Weeks 2

139 At 12 weeks, CBT (n=103), modafinil (n=107), and combination therapy (n=102) were

140 were randomly assigned to receive adjunctive modafinil (N=41) or placebo (N=44) for 6 weeks.

141 ts were randomly assigned, and 160 patients (modafinil, n = 75; placebo, n = 85) completed questionna

142 ensitivity of PFH orexin GI neurons and that modafinil normalizes glucose sensitivity of these neuron

143 otentially explaining an increased effect of modafinil observed in MCHR1 KO mice.

144 ioligand) was used to measure the effects of modafinil on extracellular dopamine and on dopamine tran

145 tudy was to investigate the acute effects of modafinil on prefrontal activation and cognitive control

146 was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic coc

147 tigate the effects of the cognitive enhancer modafinil on within-network and between-network resting-

148 k sleep disorder to receive either 200 mg of modafinil or placebo before the start of each shift.

149 Subjects received 300 mg/day modafinil or placebo during sleep restriction.

150 phrenia were studied twice, receiving either modafinil or placebo prior to functional magnetic resona

151 During modafinil or placebo treatment, the mean duration of nCP

152 nt system with minimisation, to receive CBT, modafinil, or both for 12 weeks.

153 support an indiscriminate use of amantadine, modafinil, or methylphenidate for the treatment of fatig

154 nd 37 (26%) patients to the methylphenidate, modafinil, placebo, and amantadine sequence.

155 s potentiated by methylphenidate, but not by modafinil pretreatments, indicating dopamine-dependent a

156 ysis studies demonstrated that both R- and S-modafinil produced increases in extracellular DA concent

157 pathological gambling, N-acetyl cysteine and modafinil, produced significant improvement for patholog

158 Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep arc

159 Modafinil (Provigil, Modiodal), an antinarcoleptic and m

160 is to study the pharmacological actions of R-modafinil (R-MOD) and S-modafinil (S-MOD) on nicotine-ta

161 Modafinil ((+/-)MOD) and its R-enantiomer (R-modafinil; R-MOD) have been investigated for their poten

162 For example, psychostimulants (e.g., modafinil) reduce excessive daytime sleepiness (EDS) and

163 Treatment with 200 mg of modafinil reduced the extreme sleepiness that we observe

164 Modafinil (relative to placebo) enhanced oscillatory pow

165 a-glycyrrhetinic derivatives or mefloquine), modafinil restored electrotonic coupling within 30 min.

166 Similarly, modafinil restored normal glucose sensitivity to PFH ore

167 eference behavioral test to demonstrate that modafinil reversed hypoglycemia unawareness in male mice

168 logical actions of R-modafinil (R-MOD) and S-modafinil (S-MOD) on nicotine-taking and nicotine-seekin

169 stimulants, although the exact mechanisms of modafinil's actions in wakefulness and cognitive enhance

170 These results suggest that modafinil's effects of memory are more selective than am

171 he placebo, methylphenidate, amantadine, and modafinil sequence; 35 (25%) patients to the modafinil,

172 Our results indicate that modafinil shares mechanisms with cocaine and methylpheni

173 Modafinil significantly improved daytime sleepiness, wit

174 Modafinil significantly increased the negative coupling

175 arch on alerting agents such as caffeine and modafinil that interact with the dopaminergic pathway an

176 sitivity and assesses the effects of a drug, modafinil, that increases alertness during wakefulness.

177 abuse, and considering the increasing use of modafinil, these results highlight the need for heighten

178 the initial efficacy findings for baclofen, modafinil, tiagabine, and topiramate.

179 controlled clinical trials, namely baclofen, modafinil, tiagabine, and topiramate.

180 The use of so-called 'smart drugs' such as modafinil to improve cognitive performance has recently

181 We used the pharmacological agent modafinil to promote low-tonic/high-phasic LC-NE activit

182 il acts, we administered a range of doses of modafinil to rats, recorded sleep/wake activity, and stu

183 mice, Alprazolam (to put them to sleep) and Modafinil (to wake them up).

184 in vehicle-treated cage-mates of Alprazolam/Modafinil-treated mice, suggesting that behavioral inter

185 Cx36 over-expression, modafinil treatment and S293 peptide all enhanced Cx36 g

186 Modafinil treatment in schizophrenia augments middle-fre

187 nic prolonged wakefulness in mice induced by modafinil treatment produced long-term potentiation (LTP

188 These outcomes were not affected by modafinil treatment.

189 Caffeine and modafinil, two wake-promoting agents that have no analge

190 oral amantadine (up to 100 mg twice daily), modafinil (up to 100 mg twice daily), methylphenidate (u

191 try data to estimate the association between modafinil use during early pregnancy and major congenita

192 utant compared with wild-type DAT, whereas S-modafinil was affected less.

193 Modafinil was also found to influence option generation

194 Modafinil was associated with increased daytime sleep la

195 R-modafinil was significantly less potent in the DAT Y156F

196 R- and S-modafinil were also evaluated in microdialysis studies i

197 sured by changes in binding potential) after modafinil when compared with after placebo.

198 physiological task effects were modulated by modafinil, which enhances aspects of cognitive function

199 fter taking 200 mg versus 100 mg and 0 mg of modafinil, while fluency increased linearly with dosage